ACB - Aurora Cannabis Inc.

NYSE - NYSE Delayed Price. Currency in USD
2.4500
-0.0700 (-2.78%)
At close: 4:01PM EST

2.4600 +0.01 (0.41%)
After hours: 5:19PM EST

Stock chart is not supported by your current browser
Previous Close2.5200
Open2.5200
Bid2.4400 x 36200
Ask2.4500 x 39400
Day's Range2.4400 - 2.6000
52 Week Range2.1400 - 10.3200
Volume22,728,625
Avg. Volume23,014,764
Market Cap2.6B
Beta (3Y Monthly)1.56
PE Ratio (TTM)11.34
EPS (TTM)0.2160
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • ACCESSWIRE

    SHAREHOLDER ALERT: ADTN IRBT ACB: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, NY / ACCESSWIRE / December 11, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered ...

  • GlobeNewswire

    Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aurora Cannabis Inc.

    If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On November 14, 2019, the Company released an earnings report in which it reported a 24% sequential decline in revenue of C$75.3 versus C$98.9 in the previous quarter. In addition to this decline in revenue, the Company also announced that plans to finalize construction of additional grow facilities in both Denmark and Canada have been delayed.

  • Aurora Cannabis Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aurora Cannabis To Contact The Firm
    Newsfile

    Aurora Cannabis Shareholder Alert: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Aurora Cannabis To Contact The Firm

    New York, New York--(Newsfile Corp. - December 11, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Aurora Cannabis (NYSE: ACB) ("Aurora Cannabis" or the "Company") of the January 21, 2020 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.Faruqi & Faruqi LogoIf you invested in Aurora Cannabis stock or options between September 11, 2019 and ...

  • Cannabis stocks slammed as analysts say Canopy’s new CEO faces big challenges
    MarketWatch

    Cannabis stocks slammed as analysts say Canopy’s new CEO faces big challenges

    Cannabis stocks fell Tuesday, as analysts weighing in on Canopy Growth’s new chief executive took a cautious stance, highlighting the continuing challenges facing the company.

  • ACCESSWIRE

    SHAREHOLDER ALERT: ADTN ACB FCAU: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines

    NEW YORK, NY / ACCESSWIRE / December 10, 2019 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered ...

  • GlobeNewswire

    HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Aurora Cannabis (ACB) Investors With $200k+ Losses to Contact Its Attorneys, Securities Fraud Case Filed

    Hagens Berman urges Aurora Cannabis Inc. (ACB) investors who have suffered losses in excess of $200,000 to submit their losses now to learn if they qualify to recover compensable damages. Hagens Berman is investigating whether the fraudulent period extends beyond that alleged in the complaint. The complaint alleges that Defendants misled investors about Aurora Cannabis’ business and prospects.

  • Benzinga

    Uruguay Senate Approves New Bill To Regulate Access To Medical Cannabis

    To help put a definitive end to persisting illicit cannabis markets, Uruguay's senate has passed a new bill to regulate medical marijuana. The bill, "A Comprehensive Law for the Promotion and Access to Medical and Therapeutic Cannabis," was introduced into Congress by the "Ir" sector of the “Frente Amplio” party, and approved unanimously. The new bill also presents guidelines for pharmaceutical compounding.

  • Options Traders Expect Huge Moves in Aurora (ACB) Stock
    Zacks

    Options Traders Expect Huge Moves in Aurora (ACB) Stock

    Investors need to pay close attention to Aurora (ACB) stock based on the movements in the options market lately.

  • High Tide to Acquire Remaining 49.9% of KushBar Joint Venture with 4 Retail Cannabis Locations in Alberta
    CNW Group

    High Tide to Acquire Remaining 49.9% of KushBar Joint Venture with 4 Retail Cannabis Locations in Alberta

    CALGARY , Dec. 10, 2019 /CNW/ - High Tide Inc. ("High Tide" or the "Company") (HITI.CN) (HITIF) (2LY.F), an Alberta -based, retail-focused cannabis corporation enhanced by the manufacturing and wholesale distribution of smoking accessories and cannabis lifestyle products, is pleased to announce that it has entered into a definitive share purchase agreement (the "Definitive Agreement") with 2651576 Ontario Inc. (the "Minority Holder"), a private Ontario company, to acquire the remaining 49.9% interest (the "Minority Interest") in High Tide's majority-owned subsidiary, KushBar Inc. ("KushBar"). Pursuant to the Definitive Agreement, High Tide, which presently holds a controlling interest of 50.1% in KushBar, will acquire the Minority Interest in a transaction (the "Transaction") that will result in KushBar becoming a wholly-owned subsidiary of High Tide.

  • ACCESSWIRE

    CLASS ACTION UPDATE for UA, AFI and ACB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, NY / ACCESSWIRE / December 9, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine ...

  • ACCESSWIRE

    SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aurora Cannabis Inc. - ACB

    NEW YORK, NY / ACCESSWIRE / December 9, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Aurora Cannabis Inc. ("Aurora" or the "Company") (ACB). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Aurora and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

  • Benzinga

    Benzinga Heads To Miami For The First Cannabis Capital Conference Of 2020

    DETROIT — The premier gathering of cannabis entrepreneurs and investors in North America, the Benzinga Cannabis Capital Conference , is heading to Miami in 2020 for its sixth installment. The conference, ...

  • Barrons.com

    Canopy Growth Has a New CEO. Here’s What He Needs to Do Now.

    A top task facing Canopy Growth’s newly-announced chief executive will be to control the cannabis company’s swelling expenses. Good thing that David Klein has been the financial chief at the pot producer’s big shareholder, (STZ) because his bud-counting skills will be tested by the costs of the new beverages, vapes and chocolates that Canopy starts selling in Canada next month. Investors seem happy that a financial guy is taking charge of (WEED) (ticker: CGC), whose founder Bruce Linton was forced out in July by Constellation (STZ) after the pot pioneer’s losses ballooned.

  • ACCESSWIRE

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CC, ACB and HEXO

    NEW YORK, NY / ACCESSWIRE / December 9, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate ...

  • ACCESSWIRE

    Bronstein, Gewirtz & Grossman, LLC Reminds of Class Action Against Aurora Cannabis Inc. (ACB), Baxter International Inc. (BAX) & HEXO Corp. (HEXO)

    NEW YORK, NY / ACCESSWIRE / December 9, 2019 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review ...

  • Cannabis Countdown: Top 10 Marijuana Stock News Stories Of The Week
    Benzinga

    Cannabis Countdown: Top 10 Marijuana Stock News Stories Of The Week

    Cannabis Countdown: Top 10 Marijuana Stock News Stories of the Week Welcome to the  Cannabis Countdown . In this week’s rendition, we’ll recap and countdown the top 10 marijuana stock news stories for ...

  • ACCESSWIRE

    The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of REAL, YJ and ACB

    NEW YORK, NY / ACCSSWIRE / December 8, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. Class Period: all persons and entities who purchased RealReal common stock pursuant and/or traceable to the Company's registration statement issued in connection with the Company's June 27, 2019 initial public offering.

  • Aurora Cannabis (ACB): Next Up, International Pain
    TipRanks

    Aurora Cannabis (ACB): Next Up, International Pain

    A big thesis of the Canadian cannabis LPs investment story was global expansion. The news last week of Aurora Cannabis (ACB) being blocked from Germany sales highlights the bigger problems of trying to operate in dozens of countries. With a concerning low level of cash, the cannabis giant doesn’t need another revenue problem while a competitor just opened up a potential financing source to solve the cash crunch.Unsurprisingly, investor sentiment is also very negative, with individual portfolios in the TipRanks database showing a net pullback from Aurora stock.Germany ProblemAccording to MJBizDaily, Aurora Cannabis’ medical cannabis products aren’t going to be on the Germany market until early next year at the earliest. Health authorities apparently are concerned about a “proprietary step” used by the Canadian company to ensure the shelf life of the products.The news outlet suggests Aurora Cannabis could have a problem with prescriptions following regulatory approval next year as German pharmacists move onto another product for treatment of patients. In the last quarter, the company had C$5 million in international cannabis sales with the majority of the revenues from the German market. The issue speaks to the bigger concern of trying to meet regulatory requirements in dozens of countries as the company ramps up global operations.Just last week, the company announced plans for entering Ireland. The CBD oil drops are approved by the Medical Cannabis Access Programme for three medical conditions.This news should again caution the excitement over global operations, especially considering Aurora Cannabis will report virtually nothing for ongoing international operations that were a cornerstone of the stock story.Facility Financing While investors are facing another revenue disappointment for Aurora Cannabis, the company got some good news from Aphria (APHA) and a potential game plan for resolving current cash crunch fears. The ability of Aphria to obtain a C$80 million secured loan with an interest rate in the 5% range is a very positive sign for Aurora Cannabis. The larger cannabis company has nearly C$1 billion worth of property and equipment on the balance sheet.The large cannabis company ended the last quarter with only C$237 million of cash on the balance sheet or roughly enough cash to wrap up the capital spending for the rest of FY20 ending next June. Aurora Cannabis must fund ongoing operating cash burn via funding sources such as the existing at-the-market stock offering which already sold C$107 million worth of stock in FQ2.The market would welcome low cost debt based on the massive facilities already in operation. Any anti-dilutive option is a concern with the company already having borrowings of C$282 million plus another C$283 million in convertible debt after the recent conversion of C$230 million worth of converts.Aurora Cannabis lacks the immediate path to EBITDA profits that makes Aphria a more attractive company to extend secure facilities loans.TakeawayThe key investor takeaway is that Aurora Cannabis faces more operational struggles after a big hit to their international expansion plan. The company can’t face any hits that impact the path to profitability.A low-cost loan, secured by facilities would be one strong signal that Aurora Cannabis has turned the corner. For now though, investors are best watching on the sideline waiting for the cannabis company resolve funding issues first.To find better ideas for cannabis stocks trading at fair value or better, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

  • ACCESSWIRE

    CLASS ACTION UPDATE for MMSI, ET and ACB: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

    NEW YORK, NY / ACCESSWIRE / December 6, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine ...

  • GlobeNewswire

    INVESTOR ALERT - Aurora Cannabis Inc. (ACB) - Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action and Lead Plaintiff Deadline: January 21, 2020

    Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aurora Cannabis Inc. (“Aurora” or the “Company”) (ACB) and certain of its officers, on behalf of shareholders who purchased Aurora securities between September 11, 2019 and November 14, 2019, inclusive (the “Class Period”). This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934.

  • Is the Right Move to Buy Hexo Stock Amid Cannabis Rebound?
    InvestorPlace

    Is the Right Move to Buy Hexo Stock Amid Cannabis Rebound?

    Cannabis stocks have been on the mend lately, although most are still carrying painful losses this year. Hexo (NYSE:HEXO) is not an exception to this observation. Hexo stock has been under considerable pressure, down 37% in 2019 and more than 70% from its May high.Source: Shutterstock Is the cannabis space really going to make a comeback? That much isn't clear yet, unfortunately. But we can determine which ones to buy in the event that names like Hexo stock do rebound.In November, these names fell off a cliff. I mean, really tanked hard amid relentless selling. Painful as it was, the plunge at least got the discussion going that perhaps these names were capitulating. There could still be some end-of-year selling as investors look to lock in tax losses, but positive signs are starting to emerge.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFor instance, on Tuesday, when the stock market opened lower with indexes down more than 1%, pot stocks were holding in. Then they turned positive and started to gain momentum. How could cannabis stocks be green on the day when the S&P 500 index was down 1.3% for the session?These are not high-quality equities or a flight-to-safety asset class. That got my attention and I'm now taking the charts more seriously. * 7 Stocks to Buy in December Trading Hexo Stock Click to Enlarge Source: Chart courtesy of StockCharts.comAt the beginning of summer, cannabis stocks started to swoon. I flagged a few of these breakdowns, like Canopy Growth (NYSE:CGC) and Aurora Cannabis (NYSE:ACB), cautioning investors to be careful now that key support was giving way.I didn't expect it would lead to some of the declines we've seen since. Many of these names are down 60% to 70% from the highs, while Tilray (NASDAQ:TLRY) is down 90%. Ouch!However, most of these names are rebounding from the lows -- Hexo stock included. Like I said of CGC the other day, two developments are now critical for bulls. First, Hexo stock price must avoid making new lows. It was a panic collapse that sent shares down to $1.56.Bulls also need to see Hexo stock price clear downtrend resistance (blue line). Clearing the 50-day moving average would also open things up a bit on the charts. In short, we need to stop seeing lower lows, and starting seeing higher lows develop on the chart.We're unlikely to go from a sharp downtrend to a massive uptrend overnight. There will be setbacks along the way, but we need to see these two developments before we can trust Hexo.On the chart above, investors can also see that $2 has played a key role lately. Below it should put investors on caution for a possible retest of the lows. If it can hold above $2 a share, a test of its downtrend marks will be in the cards, as well as a possible push to $3. Let's keep an eye on Hexo stock. Bottom Line on Hexo StockDo the charts make Hexo stock a buy? In a word: no. The charts show that the situation is improving from a few weeks ago, but has not signaled the all-clear to investors just yet.So what about the fundamentals?Judging cannabis stocks based on the fundamentals is difficult. That's because many have triple-digit sales growth but low revenue figures. Further, most are not free cash flow positive or profitable, yet garner valuations in the billions.Because of the large correction this year, Hexo stock now sports a market cap of $527 million. Is that too much? Well… * 7 Exciting Biotech Stocks to Buy Now Last year, Hexo had net revenue of 47.3 million CAD ($35.9 million) and lost over 86 million CAD. Investors should know that profits have been elusive for this company.That's not necessarily a nail in the coffin, but companies that are sacrificing profits for growth need to have staying power via the balance sheet. With just 113.5 million CAD in unrestricted cash, some investors have to be nervous. That's even as current assets sit at 314 million CAD, compared to just 52.6 million CAD in current liabilities.But the acceleration in liabilities -- with total liabilities up to 104.3 million CAD last quarter from 17.3 million CAD three quarters ago -- and the negative cash flow is a concern. Hexo isn't the worst pick, but amid a cannabis comeback, I prefer Aphria (NYSE:APHA) and Canopy Growth stock, which have stronger balance sheets.Bret Kenwell is the manager and author of Future Blue Chips and is on Twitter @BretKenwell. As of this writing, Bret Kenwell is long APHA. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Retail Stocks to Buy That Dominated Thanksgiving Shopping * 6 Manufacturing Stocks to Buy as the Economy Recovers * The 7 Best Cryptocurrencies to Buy as Blockchain Heats Up The post Is the Right Move to Buy Hexo Stock Amid Cannabis Rebound? appeared first on InvestorPlace.